Business
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patientsSecond cohort of trial showed 10 of the
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patientsSecond cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatmentNew combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSMAnnounced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO®INO-4201 was well-tolerated and boosted humoral responses in 36 of 36 (100%) treated participantsNew safety and immunological data indicating potential to extend protection against Ebola presented at ECCMIDAnnounced topline results for REVEAL2, the second Phase 3 trial for VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesionsAnalysis of clinical characteristics of biomarker population is ongoing; findings to be shared in third quarter 2023Trial results achieved statistical significance in all-participants populationTrial results did not meet primary endpoint in biomarker-selected populationEnhanced product development team with appointment of Dr. Cheryl Elder as Senior Vice President, Regulatory AffairsEnded the first quarter 2023 with $223.8 million in cash, cash equivalents and short-term investmentsCompany maintains cash runway projection into first quarter 2025Management will host conference call today at 4:30 p.m. EDTPLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced financial results and operational highlights for the first quarter of 2023. INOVIO's management will host its quarterly conference call and webcast today at 4:30 p.m. EDT. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.\n\"In the first quarter of 2023 we made solid progress with several key pipeline candidates, including important headway in our development plans for INO-3107, our DNA medicine candidate for the treatment of RRP,\" said INOVIO's President and Chief Executive Officer, Dr. Jacqueline Shea. \"From our ongoing discussions, we believe we are in alignment with the FDA on several cr...